Table 2.

Univariate analysis

CharacteristicPFSOS
HR (95% CI)PHR (95% CI)P
Age1.01 (0.98-1.04).4251.05 (0.99-1.11).107
Male3.73 (0.86-16.30).0801.65 (0.19-14.20).648
Stage II1.26 (0.45-3.53).6652.4 (0.28-20.65).425
ECOG PS 11.04 (0.30-3.62).9510.04 (0.00-265.72).461
Supradiaphragmatic disease3.49 (0.80-15.24).09731.38 (0.01-85 218.00).393
B symptoms0.63 (0.08-4.80).6300.05 (0.00-82 523.70).673
Extranodal disease0.64 (0.08-4.90).6702.79 (0.32-24.07).351
Variant histologic pattern0.65 (0.24-1.82).4170.39 (0.05-3.33).39
PET-CT imaging not performed3.16 (1.24-8.04).0164.38 (0.74-25.88).104
Tumor size ≥5 cm0.95 (0.27-3.34).9310.89 (0.10-7.65).913
Era of therapy
 Before 2000*
 2000-20100.55 (0.20-1.50).2400.38 (0.08-1.97).251
 2011-20170.24 (0.03-2.22).210<0.01 (0.00-1.6 × 10172).957
  • HR, hazard ratio.

  • * The reference category is treatment before 2000.